- Strongest evidence: correcting low dietary intake, migraine prevention (300–600 mg daily under medical supervision), and modest blood-pressure reduction — with meta-analyses supporting a systolic drop of ~2 mmHg (Cochrane, Journal of Human Hypertension).
- For sleep, anxiety, muscle cramps, depression, diabetes, and bone health, evidence is mixed to weak — a systematic review found only 3 low-quality RCTs (151 participants) for insomnia (Mah & Pitre 2021).
- Best form for routine supplementation: glycinate/bisglycinate (best tolerated) or citrate (better if constipation relief is also wanted); oxide is poorly absorbed and mainly useful as a laxative (NIH ODS).
- Upper safe limit from supplements: 350 mg/day for adults (NIH ODS Tolerable Upper Intake Level — this excludes food sources).
- Serious interactions with bisphosphonates, tetracycline and quinolone antibiotics, and potassium-sparing diuretics; kidney disease patients need medical guidance before supplementing.
- Evidence grade: Strong
Magnesium is essential for nerve function, muscle contraction, glucose control, blood pressure regulation, bone structure, and energy metabolism, but supplementation is not a cure-all. The strongest practical uses are correcting low intake, constipation with laxative forms, modest blood pressure support, and migraine prevention under medical supervision; sleep, anxiety, cramps, depression, diabetes, and bone claims are more mixed. For routine supplementation, magnesium glycinate/bisglycinate or citrate usually makes more sense than oxide, but people with kidney disease or interacting medicines should not self-prescribe magnesium (NIH Office of Dietary Supplements).
Table of contents
- Evidence summary
- What magnesium is
- All forms and types of magnesium
- How magnesium works
- What works and what does not
- Benefits with evidence grades
- Risks and all side effects
- All interactions
- Who should avoid magnesium
- Dosage and how to take magnesium
- Infographics with full text versions
- Frequently asked questions
- Sources and funding notes
Evidence summary
| Claim | Evidence | Source | Funding / conflict check | Strength |
|---|---|---|---|---|
| Magnesium is essential, but serum magnesium is an imperfect status marker. | NIH fact sheet summarizing physiology, intake, status assessment, and safety. | NIH ODS Magnesium Fact Sheet | U.S. government source; source country: United States; editorial incentive is public-health accuracy. | Strong |
| Citrate, chloride, lactate, and aspartate are generally more bioavailable than oxide or sulfate. | NIH summary plus small human bioavailability trials and a 2021 systematic review. | NIH ODS; Lindberg et al.; Blancquaert et al. systematic review | Lindberg: NIH grants, U.S.; no COI statement found in PubMed. Systematic review: Spain; authors declared no competing interests and no grant listed in PubMed. | Moderate |
| Sleep benefits are uncertain outside deficiency or older adults with insomnia. | Small elderly insomnia RCT and meta-analysis found limited, low-quality evidence; NCCIH states evidence is not sufficient for sleep disorders. | Abbasi et al.; Mah & Pitre systematic review; NCCIH | Abbasi: Iran, no conflict declared, grant not listed in PubMed. Mah & Pitre: Canada, no conflict declared, grant not listed. NCCIH: U.S. government. | Weak |
| Magnesium-L-threonate sleep claims are not independently established. | One 2024 RCT reported improved sleep in adults with self-reported sleep problems. | Hausenblas et al. MgT RCT | Conflicted: funded by AIDP Inc.; three authors affiliated with AIDP; Magtein supplied by Threotech; source country: United States. | Weak |
| Blood pressure lowering is real but modest. | Meta-analysis of 34 randomized double-blind placebo-controlled trials found small average BP reductions. | Zhang et al. Hypertension meta-analysis | U.S./China/Japan/Canada affiliations; no grant or COI statement listed in PubMed. | Moderate |
| Magnesium oxide and citrate can work as osmotic laxatives. | Pharmacology reviews, chronic constipation guidelines, and DailyMed OTC laxative labeling support laxative use. | Magnesium oxide review; 2023 constipation guideline; DailyMed magnesium citrate label | Japan/Belgium review had government funding but multiple pharmaceutical ties disclosed; constipation guideline funded by Japanese Gastroenterological Association and disclosed extensive industry ties, so conclusions are downgraded. | Moderate |
| Magnesium is unlikely to meaningfully prevent idiopathic muscle cramps in older adults. | Cochrane review found magnesium unlikely to provide clinically meaningful cramp prophylaxis in older adults; pregnancy evidence remains uncertain. | Cochrane muscle cramps review | Canada; CIHR support listed; one author wrote an included study but no company conflicts were known. | Moderate |
| Migraine prevention has moderate support but doses can exceed the supplement UL. | Systematic reviews and headache guidance rate magnesium as probably effective for prevention. | von Luckner & Riederer systematic review; NIH ODS migraine summary | Switzerland review; no grant or COI statement listed in PubMed. NIH is U.S. government. | Moderate |
| Diabetes and blood sugar claims are mixed. | Meta-analyses show modest improvements in some glucose markers, but NIH notes only a few small clinical trials and conflicting results. | Simental-Mendía et al.; Veronese et al./JAES meta-analysis record; NIH ODS | Mexico and Philippines/Italy-linked sources; no grant listed for key PubMed records; JAES paper declared no conflict. | Weak–Moderate |
| Bone health depends on adequate magnesium, but supplementation evidence is not strong. | Systematic reviews link intake with BMD markers more than proven fracture reduction. | Groenendijk et al.; Farsinejad-Marj et al. | Netherlands and Iran; no grants or COI statements listed in PubMed. | Weak–Moderate |
What magnesium is
Magnesium is a mineral electrolyte and enzyme cofactor, not a sedative or hormone. In the body, it participates in more than 300 enzyme systems involved in protein synthesis, muscle and nerve function, blood glucose control, blood pressure regulation, energy production, DNA/RNA synthesis, and antioxidant defenses (NIH Office of Dietary Supplements).
An adult body contains about 25 grams of magnesium, with roughly 50% to 60% in bone and most of the rest in soft tissues; less than 1% is in serum, so a normal serum result does not always prove optimal total-body magnesium status (NIH Office of Dietary Supplements). Normal serum magnesium is about 0.75 to 0.95 mmol/L, and hypomagnesemia is commonly defined below 0.75 mmol/L (NIH Office of Dietary Supplements).
The active compound — what actually does the work
The active nutrient is the magnesium ion, Mg2+. The attached compound — glycinate, citrate, oxide, malate, threonate, taurate, chloride, sulfate, orotate, or bisglycinate — mainly changes solubility, elemental magnesium percentage, GI tolerance, absorption pattern, price, and marketing claims.
Dietary magnesium versus supplemental magnesium
Food magnesium comes packaged with fiber, potassium, plant compounds, and slower absorption. Supplements deliver concentrated elemental magnesium, which is why the tolerable upper limit applies to supplemental/medicine magnesium, not magnesium naturally present in food (NIH Office of Dietary Supplements).
All forms and grades
The most important buying rule is to read the label for elemental magnesium, not the total compound weight. A tablet labeled “magnesium glycinate 2,000 mg” may not provide 2,000 mg elemental magnesium, because most of that weight is glycine plus mineral salt.
| Form | What it is | Bioavailability | Best use | Cost | Verdict |
|---|---|---|---|---|---|
| Magnesium glycinate | Magnesium bound to glycine; often sold for sleep and calm. | Likely good because chelated/organic forms are usually better tolerated than oxide, but direct head-to-head human evidence is thinner than citrate evidence. | Routine supplementation when GI sensitivity matters. | — | Best general-purpose choice, but sleep claims are stronger than the evidence. |
| Magnesium bisglycinate | Magnesium chelated with two glycine molecules; practically overlaps with “glycinate” marketing. | Likely good; form-specific independent outcome data remain limited. | Same use as glycinate: daily repletion, sensitive stomach, bedtime dosing if separated from medicines. | — | Equivalent to glycinate for most buyers; choose by elemental dose and testing transparency. |
| Magnesium citrate | Magnesium salt of citric acid. | Good; citrate outperformed oxide in small human absorption studies and is listed by NIH among better-absorbed forms (Lindberg et al., NIH ODS). | Constipation, general supplementation when looser stools are acceptable. | — | Best value if constipation is also a goal; avoid if diarrhea-prone. |
| Magnesium oxide | Magnesium plus oxygen; high elemental magnesium by weight but poorly soluble. | Lower than citrate; NIH notes oxide is less bioavailable than more soluble forms (NIH ODS). | Cheap laxative/antacid-style use, not ideal repletion. | — | Cheap but not the best absorption choice; more GI side effects. |
| Magnesium malate | Magnesium bound to malic acid. | Probably better than oxide by solubility logic, but robust independent human absorption/outcome data are limited. | Often marketed for energy and muscle pain. | Less common than glycinate/citrate; often appears in blends. | Insufficient evidence for unique benefits over citrate/glycinate. |
| Magnesium L-threonate | Magnesium salt of L-threonic acid, marketed for brain penetration and sleep/cognition. | Animal/mechanistic rationale; human outcome evidence is early and product-linked. | Not first-line; consider only if cost is acceptable and claims are treated as experimental. | — | Most over-marketed form; current sleep RCT is industry-funded (Hausenblas et al.). |
| Magnesium taurate | Magnesium bound to taurine. | Insufficient independent human bioavailability and outcomes evidence. | Marketed for heart rhythm, BP, and calm because taurine has cardiovascular roles. | — | Interesting but unproven; do not pay a premium for evidence-based outcomes. |
| Magnesium chloride | Highly soluble magnesium salt, sold as oral drops, tablets, or topical “magnesium oil.” | NIH lists chloride among forms absorbed more completely than oxide/sulfate (NIH ODS). | Oral replacement if tolerated; topical claims remain weaker than oral data. | Available, but less mainstream than glycinate/citrate. | Good soluble form; topical use should not be treated as proven systemic repletion. |
| Magnesium sulfate | Epsom salt; used medically, including IV magnesium sulfate in specific conditions, and sometimes as a laxative. | Lower oral bioavailability than soluble organic forms; NIH lists sulfate as less bioavailable than citrate/chloride/aspartate/lactate (NIH ODS). | Medical/short-term laxative uses, not routine daily supplement. | Cheap as Epsom salt; supplement use uncommon. | Not a daily wellness form; use medically guided. |
| Magnesium orotate | Magnesium bound to orotic acid. | Limited independent comparative absorption evidence. | Historically studied in severe heart failure, not general wellness. | — | Specialized and weakly supported; one heart-failure RCT exists but does not justify routine use (MACH trial). |
How it works
What the body does with it
Magnesium supports ATP-related energy reactions, glucose metabolism, nerve impulse conduction, muscle contraction, bone mineral structure, and the transport of calcium and potassium across cell membranes (NIH Office of Dietary Supplements). Kidneys regulate magnesium balance by lowering urinary excretion when magnesium status is low and clearing excess magnesium when kidney function is normal (NIH Office of Dietary Supplements).
Why form and delivery matter
Forms that dissolve well in liquid are generally absorbed better than poorly soluble forms, which is why citrate, chloride, lactate, and aspartate tend to outperform oxide and sulfate in NIH’s evidence summary (NIH Office of Dietary Supplements). The same property that makes unabsorbed magnesium stay in the gut also explains the laxative effect: unabsorbed salts draw water into the intestine and stimulate motility (NIH Office of Dietary Supplements).
What works and what does not
| Claimed benefit | Verdict | Evidence grade | What the evidence says | Key caveat |
|---|---|---|---|---|
| Sleep | MIXED | Weak | Small older-adult trials suggest possible benefit, but systematic review evidence is limited and NCCIH says evidence is not sufficient for sleep disorders (Mah & Pitre, NCCIH). | Best case is low intake/older adults; threonate data are industry-funded. |
| Stress/anxiety | INSUFFICIENT EVIDENCE | Weak | A systematic review found suggestive but poor-quality evidence for subjective anxiety and stress (Boyle et al.). | Do not replace therapy or prescribed medication. |
| Blood pressure | WORKS | Moderate | RCT meta-analyses show small BP reductions, not drug-level effects (Zhang et al.). | More relevant if intake is low or cardiometabolic risk exists. |
| Constipation | WORKS | Moderate | Magnesium salts work as osmotic laxatives, and magnesium citrate has OTC laxative labeling (DailyMed magnesium citrate). | Not suitable for kidney disease; diarrhea is dose-related. |
| Muscle cramps | DOESN’T for typical older-adult cramps | Moderate | Cochrane concluded magnesium is unlikely to provide clinically meaningful prophylaxis for idiopathic cramps in older adults (Cochrane). | Pregnancy cramp evidence remains uncertain. |
| Migraine prevention | WORKS | Moderate | Headache evidence reviews and NIH’s summary rate magnesium therapy as probably effective for prevention (von Luckner & Riederer, NIH ODS). | Common migraine doses can exceed the 350 mg/day supplemental UL, so use clinician guidance. |
| Blood sugar / diabetes | MIXED | Weak–Moderate | Meta-analyses show modest improvements in fasting glucose or insulin sensitivity in some groups, but NIH notes clinical trials are few, small, and conflicting (Simental-Mendía et al., NIH ODS). | Not a diabetes treatment replacement. |
| Bone health | MIXED | Weak–Moderate | Dietary magnesium is associated with bone mineral density, but supplementation has not clearly proven fracture prevention (Groenendijk et al., Farsinejad-Marj et al.). | Bone health still needs calcium, vitamin D, protein, resistance training, and medical risk assessment. |
| Depression | MIXED | Weak | Recent meta-analysis of depressive disorder trials suggests improvement, but trials are heterogeneous and small (2023 meta-analysis). | Use as nutrition support, not as standalone depression care. |
Benefits by claim
Sleep: popular, plausible, but not proven for everyone
Magnesium has plausible sleep mechanisms because it affects NMDA and GABA-related pathways, but clinical evidence remains limited. A small double-blind placebo-controlled trial in older adults with primary insomnia reported improvements in insomnia measures after supplementation, while a later systematic review concluded that evidence for oral magnesium in older-adult insomnia remains limited and low certainty (Abbasi et al., Mah & Pitre).
NCCIH’s current public-health position is conservative: there is not enough evidence to know whether magnesium helps sleep disorders (NCCIH). The 2024 magnesium L-threonate trial is not strong independent evidence because it was funded by AIDP Inc., included AIDP-affiliated authors, and used Magtein supplied by Threotech (Hausenblas et al.).
Evidence grade: Weak. Magnesium may help if intake is low, but a bedtime capsule is not a reliable insomnia treatment.
Stress and anxiety: suggestive but low-quality evidence
A 2017 systematic review found suggestive evidence that magnesium may improve subjective anxiety in vulnerable groups, but the authors emphasized poor study quality and heterogeneity (Boyle et al.). The same review disclosed that one author was on a Sanofi Consumer Healthcare advisory board, although Sanofi had no role in the review (Boyle et al.).
Evidence grade: Weak. Magnesium can be part of nutrition correction, but anxiety disorders need evidence-based mental health care.
Blood pressure: small but credible effect
The best evidence for a cardiometabolic benefit is blood pressure. A 2016 meta-analysis of 34 randomized double-blind placebo-controlled trials with 2,028 participants found that magnesium supplementation produced modest reductions in systolic and diastolic blood pressure (Zhang et al.).
Evidence grade: Moderate. Magnesium is a helper, not a substitute for antihypertensive medication, sodium reduction, weight management, exercise, or sleep apnea treatment.
Constipation: works through osmotic laxative action
Magnesium citrate, oxide, hydroxide, and sulfate-type products can soften stools because unabsorbed magnesium salts draw water into the bowel. DailyMed’s magnesium citrate OTC label provides age-based laxative directions and warns users to consult a doctor for kidney disease, abdominal symptoms, sudden bowel habit changes, magnesium-restricted diet, pregnancy, or breastfeeding (DailyMed magnesium citrate).
Evidence grade: Moderate for laxative effect. This is one of the clearest uses, but it is also where misuse can cause diarrhea, dehydration, electrolyte imbalance, or hypermagnesemia in vulnerable people.
Muscle cramps: usually not worth it
For idiopathic skeletal muscle cramps in older adults, Cochrane found magnesium supplementation is unlikely to provide clinically meaningful prevention (Cochrane). The same review found pregnancy-cramp evidence uncertain and less definitive (Cochrane).
Evidence grade: Moderate negative for older-adult idiopathic cramps; insufficient for pregnancy cramps.
Migraine prevention: probably effective, but dose matters
NIH summarizes that the American Academy of Neurology and American Headache Society concluded magnesium therapy is probably effective for migraine prevention (NIH Office of Dietary Supplements). A systematic review also found a plausible evidence base for magnesium in migraine prophylaxis (von Luckner & Riederer).
Evidence grade: Moderate. Because migraine-prevention doses often exceed 350 mg/day supplemental magnesium, this should be medically supervised.
Blood sugar and diabetes: possibly helpful when magnesium status is low
Magnesium participates in glucose metabolism, and low magnesium can worsen insulin resistance; however, NIH notes that clinical trials of supplemental magnesium for diabetes control are few, small, and conflicting (NIH Office of Dietary Supplements). Meta-analyses suggest improvements in insulin sensitivity or fasting glucose in some groups, especially people with diabetes or risk factors, but HbA1c effects are less consistent (Simental-Mendía et al., JAES meta-analysis record).
Evidence grade: Weak to moderate. Correct low magnesium intake; do not treat magnesium as a glucose-lowering medicine.
Bone health: necessary nutrient, weak supplement proof
Magnesium is required for structural bone development, but supplement trials do not yet show a clear fracture-prevention outcome (NIH Office of Dietary Supplements). Systematic reviews find more support for associations between magnesium intake and bone mineral density than for proven fracture reduction (Groenendijk et al., Farsinejad-Marj et al.).
Evidence grade: Weak to moderate. Food-first adequacy is sensible; high-dose supplementation solely for bones is not well proven.
Depression: emerging but not treatment-grade evidence
A 2023 meta-analysis of randomized trials in adults with depressive disorder reported that magnesium supplementation improved depression scores, and the authors declared no commercial or financial conflict (2023 meta-analysis). The field still has limitations: trials are small, varied in dose/form, and often combine magnesium with other care.
Evidence grade: Weak. Correct deficiency or low intake, but do not delay professional depression care.
Risks and all side effects
High magnesium intake from food is low risk for healthy people because kidneys eliminate excess magnesium, but high-dose supplemental or medicine magnesium can cause diarrhea, nausea, and abdominal cramping (NIH Office of Dietary Supplements). The adult tolerable upper intake level for supplemental/medicine magnesium is 350 mg/day; this UL does not include magnesium naturally present in food and drinks (NIH Office of Dietary Supplements).
| Side effect | Frequency / likelihood | Dose relationship | Forms most associated | Mechanism | What to do |
|---|---|---|---|---|---|
| Loose stools / diarrhea | Common at higher supplemental doses | More likely above the 350 mg/day supplemental UL or when using laxative products | Oxide, citrate, carbonate, chloride, gluconate; laxative salts | Unabsorbed salts draw water into the intestine and stimulate motility (NIH ODS). | Lower dose, change form, split dose, or stop if persistent. |
| Nausea and abdominal cramping | Common with high doses or laxatives | Dose-related | Citrate/oxide/hydroxide/sulfate laxative products | Osmotic bowel effect and GI irritation (NIH ODS). | Take with food if not using as laxative; reduce dose. |
| Laxative effect | Expected for citrate, hydroxide, oxide, sulfate laxative dosing | Intentional with OTC laxative doses | Citrate, oxide, hydroxide, sulfate | Osmotic water retention in bowel | Use short term unless clinician advises otherwise. |
| Low blood pressure, flushing, lethargy, weakness | Rare in healthy adults at normal doses; more likely with toxicity | Risk rises with very high doses, renal impairment, antacids/laxatives | Any magnesium salt if dose is excessive | Elevated serum magnesium depresses neuromuscular and cardiovascular function (NIH ODS). | Stop and seek medical care if severe. |
| Hypermagnesemia / magnesium toxicity | Rare but serious | NIH reports toxicity with very large laxative/antacid doses, typically >5,000 mg/day magnesium; risk rises sharply with kidney disease (NIH ODS). | Any high-dose product, especially laxatives/antacids | Kidneys cannot clear excess magnesium; serum magnesium rises | Emergency care for confusion, severe weakness, breathing difficulty, irregular heartbeat, or collapse. |
| Cardiac arrest / respiratory depression | Very rare but life-threatening | Extreme overdose or impaired renal clearance | Any high-dose magnesium source | Severe hypermagnesemia can impair conduction and neuromuscular function (NCBI Bookshelf StatPearls). | Emergency medical care. |
All interactions
Magnesium interacts mostly by binding medicines in the gut, changing magnesium status through kidney handling, or adding to physiologic effects such as lower blood pressure or muscle relaxation. People taking regular medication should separate magnesium from interacting drugs and confirm timing with a clinician or pharmacist.
| Interacts with | Type | Severity | Mechanism | Action | Source |
|---|---|---|---|---|---|
| Oral bisphosphonates: alendronate, risedronate, ibandronate | Medication | Moderate | Magnesium-rich supplements/medicines decrease bisphosphonate absorption. | Take magnesium at least 2 hours before or after oral bisphosphonates. | NIH ODS |
| Tetracycline antibiotics: doxycycline, tetracycline, minocycline, demeclocycline | Medication | High | Magnesium forms insoluble complexes that reduce antibiotic absorption. | Take antibiotic at least 2 hours before or 4–6 hours after magnesium. | NIH ODS |
| Quinolone/fluoroquinolone antibiotics: ciprofloxacin, levofloxacin, moxifloxacin, ofloxacin | Medication | High | Chelation lowers antibiotic absorption and may risk treatment failure. | Take antibiotic at least 2 hours before or 4–6 hours after magnesium. | NIH ODS |
| Loop diuretics: furosemide, bumetanide | Medication | Moderate | Chronic use increases urinary magnesium loss. | Monitor magnesium status if long-term use, cramps, arrhythmia risk, or low potassium. | NIH ODS |
| Thiazide diuretics: hydrochlorothiazide, chlorthalidone, indapamide | Medication | Moderate | Chronic use can increase urinary magnesium loss. | Monitor electrolytes; do not self-correct high doses without labs. | NIH ODS |
| Potassium-sparing diuretics: amiloride, spironolactone, eplerenone | Medication | Moderate | These reduce magnesium excretion and may raise magnesium retention. | Use cautiously, especially with kidney disease or high-dose supplements. | NIH ODS |
| Proton pump inhibitors: omeprazole, pantoprazole, esomeprazole, lansoprazole | Medication | Moderate | Long-term PPI use can cause hypomagnesemia, sometimes not corrected until PPI is stopped. | Consider serum magnesium before and during long-term use. | NIH ODS |
| Levothyroxine | Medication | Moderate | Divalent cations can reduce levothyroxine absorption; a 2025 trial found magnesium aspartate significantly reduced thyroxine exposure. | Separate by at least 4 hours and recheck TSH if timing changes. | Levothyroxine-magnesium crossover trial |
| Gabapentin | Medication | Moderate | Magnesium/aluminum antacids reduce gabapentin absorption. | Take gabapentin at least 2 hours after magnesium-containing antacids/supplements. | FDA gabapentin label |
| Eltrombopag | Medication | High | Polyvalent cations including magnesium reduce eltrombopag absorption. | Take eltrombopag at least 2 hours before or 4 hours after magnesium/minerals. | DailyMed eltrombopag label |
| Mycophenolate mofetil | Medication | Moderate–High | Magnesium/aluminum antacids can decrease mycophenolic acid exposure. | Use clinician-directed separation; DailyMed advises antacids at least 2 hours after mycophenolate. | DailyMed mycophenolate label |
| ACE inhibitors: lisinopril, enalapril, ramipril | Medication | Use caution | No classic chelation interaction, but additive blood pressure lowering is possible; kidney disease or reduced renal function increases magnesium toxicity risk. | Monitor BP and kidney function; avoid high-dose magnesium without clinician approval. | NIH ODS safety framework |
| ARBs: losartan, telmisartan, valsartan | Medication | Use caution | Additive BP lowering and renal-function context can matter. | Monitor BP; avoid laxative doses unless advised. | BP meta-analysis; NIH ODS |
| Other antihypertensives: calcium-channel blockers, beta-blockers, alpha-blockers, nitrates | Medication | Use caution | Magnesium can modestly lower blood pressure, so dizziness or additive hypotension is possible in sensitive users. | Monitor BP and symptoms when starting or increasing magnesium. | Zhang et al. |
| Antidiabetic medicines: insulin, sulfonylureas, metformin, GLP-1 drugs, SGLT2 inhibitors | Medication | Monitor | Magnesium may modestly improve glucose parameters in some people; the interaction is pharmacodynamic rather than chelation. | Monitor glucose if using higher-dose magnesium and diabetes medication. | Simental-Mendía et al.; NIH ODS |
| Chronic kidney disease or reduced eGFR | Condition | Avoid unsupervised use | Reduced renal clearance increases risk of hypermagnesemia and toxicity. | Use only with clinician guidance and labs. | NIH ODS; NCBI Bookshelf |
| GI disease or malabsorption: Crohn’s disease, celiac disease, chronic diarrhea, intestinal surgery | Condition | Monitor | These conditions can reduce magnesium absorption or increase losses. | Assess status clinically; supplement only as part of a medical plan. | NIH ODS |
| Older age | Condition | Monitor | Older adults are more likely to have lower intake, reduced absorption, higher urinary losses, and interacting medication use. | Prefer food-first correction and low-dose supplements unless prescribed. | NIH ODS |
| Calcium supplements | Supplement | Low–Moderate | Large mineral doses can compete for absorption and cause GI burden. | Split high-dose calcium and magnesium by 2+ hours if GI symptoms or absorption concerns. | NIH ODS |
| Iron supplements | Supplement | Low–Moderate | Mineral co-dosing can reduce tolerability and may interfere with absorption of some drugs/minerals. | Separate iron and magnesium if treating deficiency or using levothyroxine/antibiotics. | NIH ODS |
| Zinc supplements | Supplement | Moderate at high zinc doses | Very high zinc intake, 142 mg/day, can interfere with magnesium absorption and disrupt magnesium balance. | Avoid chronic high-dose zinc unless medically prescribed. | NIH ODS |
| Alcohol heavy use | Substance / condition | Moderate | Alcohol use disorder is a risk group for magnesium inadequacy. | Assess diet and labs; do not rely only on supplements. | NIH ODS |
| Neuromuscular blockers / IV magnesium context | Medication context | Medical supervision only | High magnesium can enhance neuromuscular blockade and depress respiration. | Relevant mainly in hospital/IV settings, not routine low-dose supplements. | NCBI Bookshelf Hypermagnesemia |
Who should avoid magnesium
Avoid self-prescribed magnesium supplements, especially laxative doses, if you have kidney disease, reduced kidney function, heart conduction problems, unexplained abdominal pain, bowel obstruction symptoms, severe dehydration, or a magnesium-restricted diet. DailyMed’s magnesium citrate label specifically tells users to ask a doctor before use if they have kidney disease, abdominal pain/nausea/vomiting, a sudden bowel habit change lasting more than 2 weeks, a magnesium-restricted diet, pregnancy, or breastfeeding (DailyMed magnesium citrate).
Children, pregnant people, lactating people, older adults with kidney impairment, and anyone taking interacting medicines should use magnesium only with individualized medical advice. The supplement UL for adults is 350 mg/day, and pediatric ULs are lower or not established for infants (NIH Office of Dietary Supplements).
Dosage and how to take magnesium
The U.S. adult RDA is 400–420 mg/day for men and 310–320 mg/day for women from food plus supplements, depending on age (NIH Office of Dietary Supplements). The adult supplement/medicine UL is 350 mg/day, not because food magnesium is dangerous, but because concentrated supplemental magnesium causes GI adverse effects and toxicity risk at higher intakes (NIH Office of Dietary Supplements).
| Goal | Practical dose range | Preferred form | Timing | Notes |
|---|---|---|---|---|
| General intake gap | 100–200 mg elemental magnesium/day | Glycinate/bisglycinate or citrate | With dinner or before bed | Stay below 350 mg/day supplemental magnesium unless supervised. |
| Sleep support | 100–200 mg elemental magnesium/day | Glycinate/bisglycinate; citrate if constipation | Evening, separated from medicines | Evidence is weak; do not escalate dose for sedation. |
| Constipation | Product-label laxative dosing | Citrate, oxide, hydroxide-type laxative products | Usually with a full glass of water | Use short term; avoid in kidney disease unless supervised (DailyMed magnesium citrate). |
| Blood pressure support | Often 240–365 mg/day in trials | Citrate/glycinate or tolerated form | Split with meals | Monitor BP if on antihypertensives. |
| Migraine prevention | Commonly around 400–600 mg/day elemental magnesium in clinical practice | Citrate, oxide, or other studied oral magnesium salts | Split dose to reduce diarrhea | Doses may exceed UL; use clinician supervision (NIH ODS). |
| Muscle cramps | Not routinely recommended | None preferred | Not applicable | Cochrane evidence does not support routine use for older-adult idiopathic cramps (Cochrane). |
Infographics with full text versions
Infographic 1: Magnesium forms head-to-head
| Magnesium Forms: Best Use & Verdict | |
|---|---|
| Form | Absorption Best use Verdict |
| Glycinate / bisglycinate | Good likely Daily, gentle Best general choice |
| Citrate | Good Constipation + value Best value/laxative |
| Oxide | Low Cheap laxative Cheap, GI-prone |
| Threonate | Early evidence Brain/sleep marketing Expensive, conflicted RCT |
| Chloride | Good soluble Replacement Useful, less common |
| Malate / taurate / orotate | Unclear Premium claims Insufficient evidence |
| Sulfate | Lower oral Medical/laxative Not daily wellness |
Text version of infographic 1
| Form | Absorption | Best use | Verdict |
|---|---|---|---|
| Glycinate/bisglycinate | Likely good | Daily gentle supplementation | Best general choice |
| Citrate | Good | Constipation plus value | Best value/laxative option |
| Oxide | Low | Cheap laxative | Cheap, more GI-prone |
| Threonate | Early evidence | Brain/sleep marketing | Expensive with conflicted RCT evidence |
| Chloride | Good soluble form | Replacement | Useful but less common |
| Malate/taurate/orotate | Unclear | Premium claims | Insufficient independent evidence |
| Sulfate | Lower oral bioavailability | Medical/laxative use | Not a daily wellness form |
Infographic 2: Evidence strength by claimed benefit
| What Magnesium Actually Helps | |
|---|---|
| Stronger | Weaker |
| Constipation | |
| Blood pressure | |
| Migraine prevention | |
| Sleep | |
| Blood sugar | |
| Anxiety/depression | |
| Muscle cramps | |
Text version of infographic 2
- Stronger evidence: constipation, modest blood pressure support, migraine prevention.
- Mixed/weak evidence: sleep, blood sugar, bone health, depression.
- Insufficient or negative evidence: anxiety/stress as a standalone treatment and typical older-adult muscle cramps.
Infographic 3: Dosing by goal
| Dose by Goal: Stay Under the UL Unless Supervised | |
|---|---|
| Daily intake gap | 100–200 mg elemental Glycinate or citrate |
| Sleep support | 100–200 mg elemental Evidence weak |
| Constipation | Use product label Citrate/oxide laxatives |
| Blood pressure | Trial doses vary Monitor BP |
| Migraine prevention | Often 400–600 mg Clinician guidance |
| Adult supplement UL350 mg/day | Food Mg not counted |
Text version of infographic 3
| Goal | Dose | Form | Caution |
|---|---|---|---|
| Daily intake gap | 100–200 mg elemental magnesium | Glycinate or citrate | Stay below adult UL unless supervised |
| Sleep support | 100–200 mg elemental magnesium | Glycinate/bisglycinate | Evidence weak |
| Constipation | Use product-label laxative dosing | Citrate/oxide/hydroxide | Avoid in kidney disease unless supervised |
| Blood pressure | Trial doses vary | Tolerated soluble forms | Monitor BP and medications |
| Migraine prevention | Often 400–600 mg/day elemental | Clinician-directed | May exceed 350 mg/day UL |
| Adult supplemental UL | 350 mg/day | All supplemental/medicine forms | Food magnesium not counted |
Infographic 4: Interaction matrix
| Interaction Matrix: Separate, Monitor, or Avoid | |
|---|---|
| Separate doses: antibiotics, bisphosphonates, levothyroxine, gabapentin, eltrombopag, mycophenolate | |
| Monitor status: loop/thiazide diuretics, long-term PPIs, alcohol use disorder, diabetes | |
| Use caution: ACE inhibitors/ARBs, potassium-sparing diuretics, antihypertensives | |
| Avoid self-prescribing: kidney disease, severe dehydration, unexplained abdominal symptoms | |
| Main mechanisms: chelation in the gut, altered kidney excretion, additive blood pressure or neuromuscular effects. |
Text version of infographic 4
- Separate doses: tetracycline antibiotics, quinolone antibiotics, bisphosphonates, levothyroxine, gabapentin, eltrombopag, and mycophenolate.
- Monitor status: loop diuretics, thiazide diuretics, long-term proton pump inhibitors, alcohol use disorder, and diabetes-related magnesium losses.
- Use caution: ACE inhibitors, ARBs, potassium-sparing diuretics, and antihypertensive medication because BP, kidney function, and electrolyte context matter.
- Avoid self-prescribing: kidney disease, severe dehydration, bowel obstruction symptoms, unexplained abdominal pain, and high-dose laxative use.
- Main mechanisms: chelation in the gut, altered kidney excretion, additive blood pressure effects, and neuromuscular effects at toxic levels.
Infographic 5: Food-first magnesium sources
| Top Food Sources of Magnesium | |
|---|---|
| Pumpkin seeds, 1 oz — 156 mg | |
| Chia seeds, 1 oz — 111 mg | |
| Almonds, 1 oz — 80 mg | |
| Boiled spinach, 1/2 cup — 78 mg | |
| Cashews, 1 oz — 74 mg | |
| Black beans, 1/2 cup — 60 mg | |
| Brown rice, 1/2 cup — 42 mg | |
| Use foods first; supplements are for gaps, specific indications, or clinician-directed repletion. |
Text version of infographic 5
| Food | Serving | Magnesium | Percent DV |
|---|---|---|---|
| Pumpkin seeds, roasted | 1 ounce | 156 mg | 37% |
| Chia seeds | 1 ounce | 111 mg | 26% |
| Almonds, dry roasted | 1 ounce | 80 mg | 19% |
| Spinach, boiled | 1/2 cup | 78 mg | 19% |
| Cashews, dry roasted | 1 ounce | 74 mg | 18% |
| Black beans, cooked | 1/2 cup | 60 mg | 14% |
| Brown rice, cooked | 1/2 cup | 42 mg | 10% |
Values are from the NIH ODS magnesium food-source table (NIH Office of Dietary Supplements).
Related research
For deeper, evidence-graded context on the conditions magnesium is most often used for, see Pure City Research's condition guides:
- Sleep: prevention and management guide
- High blood pressure: prevention and management guide
- Stress, anxiety & depression: prevention and management guide
Frequently asked questions
Does magnesium glycinate help you sleep?
Magnesium glycinate may help some people if low intake is contributing to poor sleep, but direct evidence for glycinate as a superior sleep form is not strong. A systematic review found limited evidence for oral magnesium in older adults with insomnia, and NCCIH says current evidence is insufficient to know whether magnesium helps sleep disorders (Mah & Pitre, NCCIH).
Which magnesium is best: glycinate or citrate?
Glycinate/bisglycinate is usually better for routine supplementation when GI tolerance matters, while citrate is better when constipation relief is also desired. Citrate has better direct absorption evidence than oxide, and NIH lists citrate among forms that tend to be more bioavailable than oxide and sulfate (Lindberg et al., NIH ODS).
Can I take magnesium citrate daily?
Low-dose magnesium citrate can be used as a supplement if total supplemental magnesium stays within safe limits, but laxative-dose citrate should not be used chronically without medical advice. DailyMed’s magnesium citrate label includes kidney disease and persistent bowel habit changes among situations requiring doctor advice (DailyMed magnesium citrate).
Is magnesium oxide useless?
Magnesium oxide is not useless, but it is a poor choice if the goal is maximum absorption. It is cheap, high in elemental magnesium by weight, and can work as a laxative, but NIH notes that oxide is less bioavailable than more soluble forms such as citrate and chloride (NIH Office of Dietary Supplements).
Can magnesium stop muscle cramps?
For typical idiopathic muscle cramps in older adults, the best evidence says probably not. A Cochrane review concluded magnesium is unlikely to provide clinically meaningful cramp prevention in older adults, while pregnancy-cramp evidence remains uncertain (Cochrane).
How much magnesium is too much?
For adults, the tolerable upper intake level is 350 mg/day from supplements or medicines; magnesium naturally present in food does not count toward that UL. High-dose supplements and laxatives can cause diarrhea, nausea, cramping, and rare hypermagnesemia, especially in kidney disease (NIH Office of Dietary Supplements).
Which magnesium is best for Indians?
For most Indian adults who need a supplement, glycinate/bisglycinate or citrate offers the best balance of availability, tolerability, and cost. India-specific decisions should account for FSSAI supplement regulations and the ICMR–NIN recommended dietary allowances (about 340–440 mg/day for adult men and 310–370 mg/day for adult women), which differ slightly from US values.
Can I take magnesium with antibiotics or thyroid medicine?
Do not take magnesium at the same time as tetracycline or quinolone antibiotics because magnesium can bind them and reduce absorption; NIH advises taking those antibiotics at least 2 hours before or 4–6 hours after magnesium (NIH Office of Dietary Supplements). Levothyroxine should also be separated from magnesium because magnesium can reduce thyroxine absorption (PubMed levothyroxine-magnesium trial).
Sources and funding notes
- NIH Office of Dietary Supplements. Magnesium — Health Professional Fact Sheet. U.S. government source; source country: United States; public-health agency funding and no product conflict identified. Source
- NCCIH. In the News: Magnesium Supplements for Sleep Disorders. U.S. government source; source country: United States. Source
- Lindberg JS, Zobitz MM, Poindexter JR, Pak CYC. Magnesium bioavailability from magnesium citrate and magnesium oxide. Journal of the American College of Nutrition. NIH grants listed in PubMed; source country: United States; no COI statement found in PubMed. Source
- Walker AF et al. Mg citrate found more bioavailable than other Mg preparations in a randomised, double-blind study. Magnesium Research. Grant not listed and no COI statement found in PubMed; source country: United Kingdom. Source
- Blancquaert L et al. Bioavailability of magnesium food supplements: A systematic review. Nutrition. Authors declared no competing interests; no grant listed in PubMed; source country: Spain. Source
- Abbasi B et al. The effect of magnesium supplementation on primary insomnia in elderly. Journal of Research in Medical Sciences. Conflict of interest: none declared; no grant listed in PubMed; source country: Iran. Source
- Mah J, Pitre T. Oral magnesium supplementation for insomnia in older adults: a systematic review and meta-analysis. BMC Complementary Medicine and Therapies. COI: none declared; no grant listed in PubMed; source country: Canada. Source
- Hausenblas HA et al. Magnesium-L-threonate improves sleep quality and daytime functioning in adults with self-reported sleep problems. Sleep Medicine: X. Funded by AIDP Inc.; several authors affiliated with AIDP; Magtein supplied by Threotech; source country: United States. Source
- Zhang X et al. Effects of Magnesium Supplementation on Blood Pressure. Hypertension. No grant or COI statement listed in PubMed; affiliations span United States, China, Canada, and Japan. Source
- Simental-Mendía LE et al. Effects of oral magnesium supplementation on insulin sensitivity and glucose control. Pharmacological Research. No grant or COI statement listed in PubMed; source country: Mexico. Source
- Garrison SR et al. Magnesium for skeletal muscle cramps. Cochrane Database of Systematic Reviews. CIHR support listed; one author wrote an included study; no company conflicts known; source country: Canada. Source
- von Luckner A, Riederer F. Magnesium in migraine prophylaxis — is there an evidence-based rationale? Headache. No grant or COI statement listed in PubMed; source country: Switzerland. Source
- Groenendijk I et al. Impact of magnesium on bone health in older adults. Bone. No grant or COI statement listed in PubMed; source country: Netherlands. Source
- Farsinejad-Marj M et al. Dietary magnesium intake, bone mineral density and risk of fracture. Osteoporosis International. No grant or COI statement listed in PubMed; source country: Iran. Source
- Boyle NB et al. The effects of magnesium supplementation on subjective anxiety and stress. Nutrients. Two authors declared no conflict; one author disclosed Sanofi Consumer Healthcare advisory board membership; source country: United Kingdom. Source
- 2023 meta-analysis. Magnesium supplementation beneficially affects depression in adults with depressive disorder. Frontiers in Psychiatry. Authors declared no commercial or financial conflict; source country: Iran. Source
- DailyMed. Magnesium citrate liquid label. U.S. National Library of Medicine drug-label source; source country: United States. Source
- NCBI Bookshelf / StatPearls. Hypermagnesemia. NCBI medical reference; source country: United States. Source
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.